23andMe has been a lot of things throughout its history. Founded in 2006, it’s best known as a genetic testing company that provides insights into people’s ancestry and health risks from tubes of spit they send through the mail.
It’s also a data company, having amassed a trove of DNA samples from some 10 million people who have consented to sharing their genetic information for research. And it’s a pharmaceutical company, developing its own drugs based on discoveries gleaned from its genetic datasets. “We are an unusual company,” said CEO Anne Wojcicki on an earnings call on February 7, acknowledging its different business segments.
It is also, right now, a struggling
→ Continue reading at Wired - Science